The weekly litigation news digest is live. Subscribe now

IP Verse

Dosing Regimen For Missed Doses For Long-Acting Injectable Paliperidone Esters - EP3744326

The patent EP3744326 was granted to Janssen Pharmaceutica on Dec 6, 2023. The application was filed on Mar 30, 2016 under application number EP20169861A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3744326

JANSSEN PHARMACEUTICA
Application Number
EP20169861A
Filing Date
Mar 30, 2016
Status
Granted And Under Opposition
Nov 3, 2023
Publication Date
Dec 6, 2023
External Links
Slate, Register, Google Patents

Patent Summary

A method for reinitiating treatment with a 3-month paliperidone palmitate extended-release injectable suspension in patients who have missed their scheduled doses. The method involves administering the medication at intervals of up to 9 months after the initial treatment period, with dosing windows of 4-9 months. This approach enables patients to maintain treatment efficacy while minimizing the risk of relapse due to nonadherence. The dosing regimen is achieved through precise administration of the medication using fine needles, ensuring optimal absorption and therapeutic effect.

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
ADVANZ PHARMA SERVICES UKSep 6, 2024FUCHS PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
APPLEYARD LEESSep 5, 2024APPLEYARD LEESADMISSIBLE
HOFFMANN EITLESep 5, 2024HOFFMANN EITLEADMISSIBLE
STADA ARZNEIMITTELSep 5, 2024HAMM & WITTKOPPADMISSIBLE
ELKINGTON AND FIFESep 4, 2024ELKINGTON AND FIFEADMISSIBLE
SANDOZSep 4, 2024MAIWALDADMISSIBLE
STRAWMANSep 4, 2024VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE
ACCORD HEALTHCAREAug 28, 2024BRAND MURRAY FULLERADMISSIBLE
TEVA PHARMACEUTICALSAug 28, 2024D YOUNGADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2009163519
DESCRIPTIONUS5254556
DESCRIPTIONUS6077843
DESCRIPTIONUS6555544
DESCRIPTIONWO2006114384
OPPOSITIONUS2009163519
OPPOSITIONUS2011105536
OPPOSITIONWO2011053829
OPPOSITIONWO2016164218
OTHERWO2016164218
SEARCHUS2009163519
SEARCHUS2011105536

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents